April 17, 2018 — The U.S. Food and Drug Administration today approved Crysvita (burosumab), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets. XLH…Original Article
FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia
